Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Minnesota Stocks
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Femasys Inc (NQ: FEMY )

1.165 +0.035 (+3.10%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Femasys Inc

< Previous 1 2 3 4 5 6 7 8 Next >
Femasys Expands Commercial Management Team with Addition of Experienced New Hires
Team to Drive Strategic Initiatives, Launching Efforts at 2024 ACOG Meeting 
From Femasys Inc.
Via GlobeNewswire
Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women’s Healthcare Initiatives
From Femasys Inc.
Via GlobeNewswire
FEMY Stock Earnings: Femasys Beats EPS, Misses Revenue for Q4 2023
FEMY stock results show that Femasys beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace
Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update
Following FDA Clearance of FemaSeed®, Company Secures Capital to Support Commercial Initiatives; Cash Expected to Fund Operations Into 2H 2025 
From Femasys Inc.
Via GlobeNewswire
Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape
-- CEO Kathy Lee-Sepsick and Chief Medical Officer James Liu to Join Jones Trading Analyst Catherine Novack in a Conversation on Current Treatment Options in Infertility Including FemaSeed® at 1PM ET... 
From Femasys Inc.
Via GlobeNewswire
Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility
From Femasys Inc.
Via GlobeNewswire
Femasys to Participate in Fireside Chat to Discuss the Infertility Treatment Landscape on March 21, 2024
From Femasys Inc.
Via GlobeNewswire
Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution
From Femasys Inc.
Via GlobeNewswire
Femasys’ FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF
From Femasys Inc.
Via GlobeNewswire
First Lady Jill Biden Unveils $100M In Federal Funding To Support R&D - Watch Out for These Women Health Stocks
Jill Biden announces $100 million in federal funding for women's health research, addressing underfunding and lack of awareness. ARPA-H Sprint for Women's Health aims to promote innovative solutions. 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Femasys Inc. Advances Commercial Readiness with Appointment of Richard Spector to New Position of Chief Commercial Officer
From Femasys Inc.
Via GlobeNewswire
Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at UC Davis Medical Center, a Hub for Innovation and Groundbreaking Research in Health Care for Women
From Femasys Inc.
Via GlobeNewswire
Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at University of Utah, an Internationally Recognized Center in Obstetrics and Gynecology
From Femasys Inc.
Via GlobeNewswire
Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at Stanford Medicine
From Femasys Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Femasys Inc. Announces the Appointment of James Liu, M.D., as Chief Medical Officer
-- Thought leader from top-ranked academic gynecology program to lead clinical and medical affairs at Femasys -- 
From Femasys Inc.
Via GlobeNewswire
Femasys Inc. Completes Enrollment of FemaSeed Pivotal Trial in Support of Commercial Launch
From Femasys Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women’s Health Innovator Femasys, Inc.
From PharmaCyte Biotech, Inc.
Via Business Wire
Femasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte Biotech
From Femasys Inc.
Via GlobeNewswire
Femasys Inc. Announces Financial Results for the Third Quarter Ended September 30, 2023 and Provides Corporate Update
From Femasys Inc.
Via GlobeNewswire
Why JetBlue Airways Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers SciSparc Ltd. (NASDAQ: SPRC) shares climbed 80% to $6.14 after the company announced it received notice of acceptance from the Australian patent office for its patent application for... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Femasys Inc. EU MDR Final Audit Successfully Completed
From Femasys Inc.
Via GlobeNewswire
Femasys Inc. to Showcase FemBloc and its other Novel Products Advancing Women’s Health at the American Association of Gynecologic Laparoscopic Surgeons
From Femasys Inc.
Via GlobeNewswire
Femasys Inc. Regains Compliance with Nasdaq Listing Requirements
From Femasys Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.